🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥THRIVE (KCSG LU23-09): Rivoceranib in Patients With Pretreated Metastatic Thymic Epithelial Tumors: Phase II Multi-Center Trial 🎙️Dr. Sehhoon Park 🔢4155RO 🎯Confirmed ORR 35.0%, DCR 85.0% (n=40); Median PFS 11.8mo (13.6-Mo Follow-Up) 🎯Grade≥3 TRAEs 55.0% (Hypertension 22.5%, Proteinuria 17.5%), No Grade 5 Events ☑️NCT06200233 🔗 https://t.co/a1n3LKUDDS @OncoAlert @Larvol @myESMO @IASLC